Can the pharmaceutical industry reduce attrition rates?
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Part of the attrition may be due to low animal-to-human translational success rates; the so-called “translational failure” [3].”
From Animal to human translation: a systematic scoping review of reported concordance rates (2019) · cites this paper as [3]
In the citing paper
“Even so, late-stage attritions are still frequent [11].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [11]
In the citing paper
“Inhibition of the hERG channel can be an indicator of the APD prolongation and cardiotoxicity in early stages of drug development [11].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [11]
In the citing paper
“Less than 20 years ago, developing a drug took ~12 years, cost under a billion dollars, and the biggest challenges were failures due to efficacy or toxicity-induced attrition2.”
From Exploiting machine learning for end-to-end drug discovery and development (2019) · cites this paper as [2]
Citations
Cites
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265 · cited 1×
“In 2001, the costs of discovering and developing a drug were of the order of US d804 millio”
BackgroundRoberds, S. L. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.12.1317 · Cited by 705 · cited 1×
“We have, in a similar manner, provided very strong evidence that inhibition of β-secretase inhibits the production of amyloid-β in knockout mic”
ResultGowen, M., Lazner, F., Dodds, R., Kapadia, R., Feild, J., Tavaria, M., Bertoncello, I., Drake, F., Zavarselk, S., Tellis, I., et al. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.10.1654 · Cited by 490
Self-citationMa, P., & Zemmel, R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd884 · Cited by 174
Booth, B. L., Glassman, R. H., & Ma, P. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1158 · Cited by 84
An animal model for pycnodysostosis: the role of cathepsin K in bone remodelling
Lazner, F., Gowen, M., & Kola, I. (1999) · Molecular Medicine Today · doi:10.1016/s1357-4310(99)01563-4 · Cited by 18 · cited 1×
“and that cathepsin K is involved in bone resorption (further compelling proof of mechanism is provided by humans with pycnodysostosi”
BackgroundSelf-citation2003 approvals: a year of innovation and upward trends
Frantz, S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1327 · Cited by 15
Research works printed but not linked: 4
- Kola, I. & Rafferty, M. New technologies that may impact drug discovery in the 5–10 year timeframe workshop. 2002 Biomed. Expo Ann Arbor Michigan (data derived from Prous Science, Drugs News Prospect (2002).
- Fearn, C. J. IMS Health. The World Pharmaceutical Market Presented at the Strategic Management Review, Australia, 19–20 June (2002).
- Benjamin, G. A. & Lumley, C. E. Industry Success Rates 2003 Including Trends in Success Rates CMR Report Number 03–202 R (CMR International Surrey, UK, 2003).
- Van den Haak, M. A., Palachandran, J. & Benjamin, G. A. Performance Metrics in Global Pharmaceutical R&D, Company specific review 2002 for Merck & Co. (CMR International, Surrey, UK, 2003).
Cited by
Items 501–600 of 1,025
ADDME – Avoiding Drug Development Mistakes Early: central nervous system drug discovery perspective
Tsaioun, K., Bottlaender, M., Mabondzo, A., & the Alzheimer's Drug Discovery Foundation (2009) · BMC Neurology · doi:10.1186/1471-2377-9-s1-s1 · Cited by 103
“early recognition of problems that would make a compound unlikely to succeed in development [4].”
BackgroundBenchmarking safety pharmacology regulatory packages and best practice
Lindgren, S., Bass, A. S., Briscoe, R., Bruse, K., Friedrichs, G. S., Kallman, M. J., Markgraf, C., Patmore, L., & Pugsley, M. K. (2008) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2008.07.001 · Cited by 109
Evaluation of Serum Bile Acid Profiles as Biomarkers of Liver Injury in Rodents
Luo, L., Schomaker, S., Houle, C., Aubrecht, J., & Colangelo, J. L. (2014) · Toxicological Sciences · doi:10.1093/toxsci/kft221 · Cited by 108
Vlieghe, P., & Khrestchatisky, M. (2013) · Medicinal Research Reviews · doi:10.1002/med.21252 · Cited by 105
Predicting Harms and Benefits in Translational Trials: Ethics, Evidence, and Uncertainty
Kimmelman, J., & London, A. J. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1001010 · Cited by 111
“licensed [12,13].”
Yildirim, O., Gottwald, M., Schüler, P., & Michel, M. C. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00461 · Cited by 117
Yap, T. A., & Workman, P. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134532 · Cited by 106
The potential of induced pluripotent stem cell derived hepatocytes
Hannoun, Z., Steichen, C., Dianat, N., Weber, A., & Dubart‐Kupperschmitt, A. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.02.025 · Cited by 113
“During the recruitment process; 43% of the candidates fail due to lack of effectiveness and 33% due to the formation of negative side effects [101].”
BackgroundTwo-Dimensional (2D) and Three-Dimensional (3D) Cell Culturing in Drug Discovery
Joseph, J. S., Malindisa, S. T., & Ntwasa, M. M. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.81552 · Cited by 132
“In part, termination of the development process is due to failure at late preclinical stages of development at great expenditure [1].”
BackgroundApplication of network link prediction in drug discovery
Abbas, K., Abbasi, A., Dong, S., Ling, N., Yu, L., Chen, B., Cai, S., & Hasan, Q. (2021) · BMC Bioinformatics · doi:10.1186/s12859-021-04082-y · Cited by 122
Li, M., Lu, Z., Wu, Y., & Li, Y. (2022) · Bioinformatics · doi:10.1093/bioinformatics/btac035 · Cited by 107
Aliper, A., Kudrin, R., Polykovskiy, D., Kamya, P., Tutubalina, E., Chen, S., Ren, F., & Zhavoronkov, A. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3008 · Cited by 89
Flow perfusion effects on three-dimensional culture and drug sensitivity of Ewing sarcoma
Santoro, M., Lamhamedi-Cherradi, S.-E., Menegaz, B. A., Ludwig, J. A., & Mikos, A. G. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1506684112 · Cited by 105
“The inability of 2D systems to mimic this key element has generally resulted in preclinical findings that overstate drug activity when subsequently tested in human clinical trials, therefore undermining the drug discovery process in cancer therapies (2).”
BackgroundScott, C. W., Zhang, X., Abi-Gerges, N., Lamore, S. D., Abassi, Y. A., & Peters, M. F. (2014) · Toxicological Sciences · doi:10.1093/toxsci/kfu186 · Cited by 102
“long and expensive process which typically involves a decade or more of resource-intensive work with a high failure rate (Kola and Landis, 2004; Munos, 2009).”
BackgroundCombining Zebrafish and CRISPR/Cas9: Toward a More Efficient Drug Discovery Pipeline
Cornet, C., Donato, V. D., & Terriente, J. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00703 · Cited by 117
Badr-Eldin, S. M., Aldawsari, H. M., Kotta, S., Deb, P. K., & Venugopala, K. N. (2022) · Pharmaceuticals · doi:10.3390/ph15080926 · Cited by 118
“The accomplishment of 3D-culture models in early drug discovery has been widely adopted nowadays by the pharmaceutical research and development sectors [10-12].”
BackgroundMotif mediated protein-protein interactions as drug targets
Corbi‐Verge, C., & Kim, P. M. (2016) · Cell Communication and Signaling · doi:10.1186/s12964-016-0131-4 · Cited by 116
“recent methodologies have helped to provide increasing information, many such interactions remain undetected and thus can’t be inhibited for therapeutic effect [35, 36].”
BackgroundGlassman, P. M., Villa, C. H., Ukidve, A., Zhao, Z., Smith, P. N., Mitragotri, S., Russell, A. J., Brenner, J. S., & Muzykantov, V. R. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12050440 · Cited by 113
“In the early 1990s, poor understanding of pharmacokinetics early in development resulted in PK being the most common reason for attrition (40%) during clinical trials; however, by the end of the decade, this had fallen to less than 10% of failures, as early, thorough characterization of PK became more common [76].”
BackgroundCao, D., Wang, J., Zhou, R., Li, Y., Yu, H., & Hou, T. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300112j · Cited by 105
GPCR-targeting nanobodies: attractive research tools, diagnostics, and therapeutics
Mujić-Delić, A., de Wit, R. H., Verkaar, F., & Smit, M. J. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.03.003 · Cited by 105
Reproducibility and Rigor in Animal-Based Research
Macleod, M., & Mohan, S. (2019) · ILAR Journal · doi:10.1093/ilar/ilz015 · Cited by 104
“greater challenges in translation, [45] perhaps because potential treatment effects are smaller or take longer to become manifest, but rigorous approaches to research are in our view important in increasing value across all research domains.”
BackgroundReichel, A., & Lienau, P. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_26 · Cited by 116
Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development
Thompson, R. A., Isin, E. M., Li, Y., Weaver, R. J., Weidolf, L. O. G., Wilson, I. D., Claesson, A., Page, K., Dolgos, H., & Kenna, J. G. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.11.002 · Cited by 109
The Mycobacterium tuberculosis Drugome and Its Polypharmacological Implications
Kinnings, S., Xie, L., Fung, K. H., Jackson, R. M., Xie, L., & Bourne, P. E. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000976 · Cited by 110
“It is estimated that more than 90% of drug candidates fail during the late stages of drug development, mainly due to poor efficacy or safety [71].”
BackgroundDrug bioactivation and protein adduct formation in the pathogenesis of drug-induced toxicity
Park, B. K., Laverty, H., Srivastava, A., Antoine, D. J., Naisbitt, D. J., & Williams, D. P. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.09.011 · Cited by 109
Huang, Y., Wang, S., Guo, Q., Kessel, S. L., Rubinoff, I., Chan, L. L., Li, P., Liu, Y., Qiu, J., & Zhou, C. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0821 · Cited by 110
“4 Introduction More than 90% of cancer drugs in development fail because of lack of efficacy or unexpected toxicity in clinical trials (1-3).”
Moseson, D. E., Bien, T. T., Karunakaran, B., Ambardekar, R., & Hiew, T. N. (2024) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2024.100259 · Cited by 117
“While solubility and bioavailability were identified as accounting for ~40% of drug compound attrition in 1991 (Kola and Landis, 2004), technological advancements in strategies to address the solubility limitation, such as ASDs, have resulted in successful development of poorly water-soluble drugs…”
BackgroundGenetic programming for computational pharmacokinetics in drug discovery and development
Archetti, F., Lanzeni, S., Messina, E., & Vanneschi, L. (2007) · Genetic Programming and Evolvable Machines · doi:10.1007/s10710-007-9040-z · Cited by 104
“It is interesting to remark that, both in 1991 [1] and in 2000 [2], a considerable fraction of attritions (i.”
BackgroundDesigning Phase 0 Cancer Clinical Trials
Murgo, A. J., Kummar, S., Rubinstein, L., Gutierrez, M. E., Collins, J. M., Kinders, R. J., Parchment, R. E., Ji, J. J., Steinberg, S. M., Yang, S. X., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4560 · Cited by 104
“Despite steadily increasing investment, only about 1 in every 10 new molecular entities entering clinical development progresses to Food and Drug Administration marketing approval (1).”
BackgroundKalgutkar, A. S. S., & Didiuk, M. T. (2009) · Chemistry & Biodiversity · doi:10.1002/cbdv.200900055 · Cited by 107
Cell-based high-content screening of small-molecule libraries
Korn, K., & Krausz, E. (2007) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2007.08.030 · Cited by 104
Predicting the active doses in humans from animal studies: A novel approach in oncology
Rocchetti, M., Simeoni, M., Pesenti, E. A., Nicolao, G. D., & Poggesi, I. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.05.011 · Cited by 104
Human pluripotent stem cells in drug discovery and predictive toxicology
Laustriat, D., Gide, J., & Peschanski, M. (2010) · Biochemical Society Transactions · doi:10.1042/bst0381051 · Cited by 101
Accomasso, L., Cristallini, C., & Giachino, C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00228 · Cited by 109
“…the statement that “targeted delivery will revolutionize disease treatment” (Duncan and Gaspar, 2011) and theranostic applications, having the possibility to combine in the same disease intervention both diagnosis (through imaging) and treatment (through thermal ablation) (Lammers et al., 2011).”
BackgroundKG-Predict: A knowledge graph computational framework for drug repurposing
Gao, Z., Ding, P., & Xu, R. (2022) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2022.104133 · Cited by 117
A ‘rule of 0.5’ for the metabolite-likeness of approved pharmaceutical drugs
O’Hagan, S., Swainston, N., Handl, J., & Kell, D. B. (2014) · Metabolomics · doi:10.1007/s11306-014-0733-z · Cited by 109
“This has therefore led to concepts such as ‘‘drug-likeness’’ (e.g. Empfield and Leeson 2010; Hay et al. 2014; Kell 2013; Kola 2008; Kola and Landis 2004; van der Greef and McBurney 2005), ‘‘lead-likeness’’ (Gozalbes and Pineda-Lucena 2011; Holdgate 2007; Oprea et al. 2007, 2001; Wunberg et al.…”
BackgroundPhase II Trials in Journal of Clinical Oncology
Cannistra, S. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.1811 · Cited by 103
Network-Based Approaches in Drug Discovery and Early Development
Harrold, J. M., Ramanathan, M., & Mager, D. E. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.176 · Cited by 96
Janga, S. C., & Tzakos, A. G. (2009) · Molecular BioSystems · doi:10.1039/b908147j · Cited by 110
Disciplined approach to drug discovery and early development
Plenge, R. M. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2608 · Cited by 101
The promises of quantitative systems pharmacology modelling for drug development
Knight-Schrijver, V. R., Chelliah, V., Cucurull-Sanchez, L., & Le Novère, N. (2016) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2016.09.002 · Cited by 97
“At this time, and possibly resulting from this sudden interest, kinetics-mediated drug attrition in clinical phases was dramatically reduced [10].”
BackgroundInfluentialA systems-level framework for drug discovery identifies Csf1R as an anti-epileptic drug target
Srivastava, P. K., van Eyll, J. M., Godard, P., Mazzuferi, M., Delahaye‐Duriez, A., Steenwinckel, J. V., Gressèns, P., Danis, B., Vandenplas, C., Foerch, P., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06008-4 · Cited by 111
Current and future trends in the application of HPLC-MS to metabolite-identification studies
Castro‐Perez, J. M. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.01.007 · Cited by 102
From alternative methods to a new toxicology
Härtung, T. (2010) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2010.12.027 · Cited by 112
Sridhara, R., Johnson, J. R., Justice, R., Keegan, P., Chakravarty, A., & Pazdur, R. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp515 · Cited by 99
“(60) to 74% (61)] are discontinued before regulatory submission.”
BackgroundValidation and implementation of a novel high-throughput behavioral phenotyping instrument for mice
Brodkin, J., Frank, D., Grippo, R., Hausfater, M., Gulinello, M., Achterholt, N., & Gutzen, C. (2014) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2013.12.010 · Cited by 97
“The high rate of attrition or these drugs can be attributed to a lack of efficacy especially n the early stages of their development (Kola and Landis, 2004).”
Chemokine Receptor-Specific Antibodies in Cancer Immunotherapy: Achievements and Challenges
Vela, M., Aris, M., Llorente, M., García‐Sanz, J. A., & Kremer, L. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00012 · Cited by 115
Network Neighbors of Drug Targets Contribute to Drug Side-Effect Similarity
Brouwers, L., Iskar, M., Zeller, G., van Noort, V., & Bork, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022187 · Cited by 106
“As almost 30% of drug candidates fail in clinical stages of drug discovery due to toxicity or concerns about clinical safety [1], an increased understanding of unwanted side effects and drug action is desirable.”
BackgroundMolecular Design for Enhancement of Ocular Penetration
Shirasaki, Y. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21200 · Cited by 107
Smith, C. M., Nolan, C. K., Edwards, M., Hatfield, J. B., Stewart, T. W., Ferguson, S. S., LeCluyse, E. L., & Sahi, J. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23262 · Cited by 103
Molecular imaging with SPECT as a tool for drug development
Gomes, C. M., Abrunhosa, A. J., Ramos, P., & Pauwels, E. K. J. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.09.015 · Cited by 100
A framework to assess the translation of safety pharmacology data to humans
Valentin, J., Bialecki, R., Ewart, L. C., Hammond, T. G., Leishman, D. J., Lindgren, S., Martínez, V., Pollard, C. E., Redfern, W. S., & Wallis, R. (2009) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2009.05.011 · Cited by 105
Jain, S., Aresu, L., Comazzi, S., Shi, J., Worrall, E. G., Clayton, J., Humphries, W., Hemmington, S., Davis, P. J., Murray, E., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0148366 · Cited by 100
Phenotypes associated with genes encoding drug targets are predictive of clinical trial side effects
Nguyen, P. A., Born, D. A., Deaton, A. M., Nioi, P., & Ward, L. D. (2019) · Nature Communications · doi:10.1038/s41467-019-09407-3 · Cited by 101
Challenges in the Search for Drugs to Treat Central Nervous System Disorders
Enna, S. J., & Williams, M. C. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.143420 · Cited by 107
Target Repurposing for Neglected Diseases
Pollastri, M. P., & Campbell, R. K. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.92 · Cited by 103
“Failure rates for anti-infective drugs exceed 70% in clinical trials [2].”
BackgroundThe current status of biomarkers for predicting toxicity
Campion, S., Aubrecht, J., Boekelheide, K., Brewster, D. W., Vaidya, V. S., Anderson, L., Burt, D., Dere, E., Hwang, K., Pacheco, S., et al. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.827170 · Cited by 97
“Although animals are the best model we have at the moment for predicting adverse human effects, there is still significant attrition in drug development, which can be attributed, in part, to adverse findings in preclinical toxicology studies, with no way of safely monitoring this toxicity in the clinic, resulting in a…”
BackgroundDi, L., Feng, B., Goosen, T. C., Lai, Y., Steyn, S. J., Varma, M. V. S., & Obach, R. S. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.054031 · Cited by 107
“, very short half-life and/or very high oral clearance) (Kola and Landis, 2004).”
BackgroundImproving Physical Properties via CH Oxidation: Chemical and Enzymatic Approaches
Michaudel, Q., Journot, G., Regueiro‐Ren, A., Goswami, A., Guo, Z., Tully, T. P., Zou, L., Ramabhadran, R. O., Houk, K. N., & Baran, P. S. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201407016 · Cited by 101
Companion animals in comparative oncology: One Medicine in action
Garden, O. A., Volk, S. W., Mason, N. J., & Perry, J. A. (2018) · The Veterinary Journal · doi:10.1016/j.tvjl.2018.08.008 · Cited by 109
Molecular chameleons in drug discovery
Poongavanam, V., Wieske, L. H. E., Peintner, S., Erdélyi, M., & Kihlberg, J. O. (2023) · Nature Reviews Chemistry · doi:10.1038/s41570-023-00563-1 · Cited by 107
“In the late 1900s poor pharmacokinetics, such as suboptimal absorption, distribution, metabolism and excretion, was the major reason for the failure of drug candidates to reach the market 83 .”
Unfinished business: target-based drug discovery
Brown, D. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.10.017 · Cited by 98
Repurposing the Antihelmintic Mebendazole as a Hedgehog Inhibitor
Larsen, A. R., Bai, R.-Y., Chung, J. H., Borodovsky, A., Rudin, C. M., Riggins, G. J., & Bunz, F. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0755-t · Cited by 96
“Unanticipated toxicities at all stages of development are a major cause of failure (43).”
On the design of complex drug candidate syntheses in the pharmaceutical industry
Eastgate, M. D., Schmidt, M. A., & Fandrick, K. R. (2017) · Nature Reviews Chemistry · doi:10.1038/s41570-017-0016 · Cited by 98
Hsp90 Inhibitors in the Clinic
Pacey, S., Banerj, U., Judson, I. R., & Workman, P. (2005) · Springer eBooks · doi:10.1007/3-540-29717-0_14 · Cited by 110
“3 Phases of clinical trials used in developing new drugs (Kola and Landis, 2004; Nottage and Siu 2002; Scherer 2004)”
BackgroundSams‐Dodd, F. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.10.010 · Cited by 97
ZeGlobalTox: An Innovative Approach to Address Organ Drug Toxicity Using Zebrafish
Cornet, C., Calzolari, S., Prieto, R. M., Dyballa, S., van Doornmalen, E. J. P., Rutjes, H., Savy, T., D’Amico, D., & Terriente, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040864 · Cited by 103
Predicting human liver microsomal stability with machine learning techniques
Sakiyama, Y., Yuki, H., Moriya, T., Hattori, K., Suzuki, M., Shimada, K., & Honma, T. (2007) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2007.06.005 · Cited by 103
Li, J., Lu, C. C., Jiang, M., Niu, X., Guo, H., Li, L., Bian, Z., Lin, N., & Lü, A. (2012) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2012/149762 · Cited by 107
Zuppinger, C. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.11.036 · Cited by 105
Appraising iniparib, the PARP inhibitor that never was—what must we learn?
Mateo, J., Ong, M., Tan, D. S. P., Gonzalez, M. A., & de Bono, J. S. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.177 · Cited by 96
Screening of natural products for therapeutic activity against solid tumors.
El-Menshawi, B. S., Fayad, W., Mahmoud, K. M., El-hallouty, S. M., El‐Manawaty, M. A., Olofsson, M. H., & Linder, S. T. (2010) · PubMed · Cited by 118
Electroencephalography and analgesics
Malver, L. P., Brokjær, A., Staahl, C., Graversen, C., Andresen, T., & Drewes, A. M. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12137 · Cited by 103
The application of human embryonic stem cell technologies to drug discovery
Sartipy, P., Björquist, P., Strehl, R., & Hyllner, J. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.07.005 · Cited by 105
The Fallopian Tube as the Origin of High Grade Serous Ovarian Cancer: Review of a Paradigm Shift
Reade, C. J., Mcvey, R., Tone, A. A., Finlayson, S. J., McAlpine, J. N., Fung‐Kee‐Fung, M., & Ferguson, S. E. (2014) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(15)30659-9 · Cited by 124
Tinnitus: network pathophysiology-network pharmacology
Elgoyhen, A. B., Langguth, B., Vanneste, S., & De Ridder, D. (2012) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2012.00001 · Cited by 96
“Even more striking, there has been a worrying rise in late-stage phase 2 and phase 3 attrition, that is leading to a reduction in revenues and a financial shock to the pharmaceutical industry (Kola and Landis, 2004; Hopkins, 2007, 2008).”
Karekla, E., Liao, W.-J., Sharp, B., Pugh, J., Reid, H., Quesne, J. L., Moore, D., Pritchard, C., MacFarlane, M., & Pringle, J. H. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1121 · Cited by 89
“Despite this momentum, late-stage failures are a reality and there is <11% success in bringing a drug to market (6), attributable in part to nonpredictive preclinical drug platforms (7,8).”
BackgroundLessons Learned from Two Decades of Anticancer Drugs
Liu, Z., Delavan, B., Roberts, R., & Tong, W. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.06.005 · Cited by 94
“Less than 5% of anticancer compounds developed reach the market [5].”
BackgroundConcepts and Challenges in Quantitative Pharmacology and Model-Based Drug Development
Zhang, L., Pfister, M., & Meibohm, B. (2008) · The AAPS Journal · doi:10.1208/s12248-008-9062-3 · Cited by 95
Jonsson, M. K. B., Wang, Q.-D., & Becker, B. (2011) · ASSAY and Drug Development Technologies · doi:10.1089/adt.2011.0396 · Cited by 94
“Only one out of nine compounds that started a clinical trial during the last decade of the 20th century resulted in a registration.(1)”
Banham, G. D., Flint, S. M., Torpey, N., Lyons, P. A., Shanahan, D. N., Gibson, A., Watson, C. J. E., O’Sullivan, A.-M., Chadwick, J., Foster, K., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30984-x · Cited by 97
Application of LC/MS to proteomics studies: current status and future prospects
Chen, G., & Pramanik, B. N. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.02.007 · Cited by 94
Randomized Phase II Trials: A Long-term Investment With Promising Returns
Sharma, M. R., Stadler, W. M., & Ratain, M. J. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr218 · Cited by 94
Timm, D. M., Chen, J., Sing, D., Gage, J. A., Haisler, W. L., Neeley, S. K., Raphael, R. M., Dehghani, M., Rosenblatt, K. P., Killian, T. C., et al. (2013) · Scientific Reports · doi:10.1038/srep03000 · Cited by 93
Is it time for a paradigm shift in drug research and development in endometriosis/adenomyosis?
Guo, S.-W., & Groothuis, P. G. (2018) · Human Reproduction Update · doi:10.1093/humupd/dmy020 · Cited by 95
“This is not unusual as most drug development programs fail after reaching the clinical stage, and in this regard Women’s Health programs have the worst performance (Kola and Landis, 2004).”
BackgroundTien, A., Li, J., Bao, X., Derogatis, A., Kim, S., Mehta, S. V., & Sanai, N. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0133 · Cited by 100
“of patients, and microdosing of the experimental agent (9, 10).”
BackgroundLevelling the Translational Gap for Animal to Human Efficacy Data
Ferreira, G. S., Veening-Griffioen, D. H., Boon, W., Moors, E. H. M., & van Meer, P. J. K. (2020) · Animals · doi:10.3390/ani10071199 · Cited by 105
“The pitfalls of using animals to simulate human conditions, such as different aetiology and lack of genetic heterogeneity, have been widely recognised for a long time [1,10,19,20].”
BackgroundFood for thought... on the economics of animal testing
Bottini, A. (2009) · ALTEX · doi:10.14573/altex.2009.1.3 · Cited by 88
“A considerable number (8-30%) of drug candidates fail because of safety problems in humans (Kola and landis, 2004) in the clinical phase of evaluation despite having passed the entire toxicological programme.”
BackgroundFailures in Phase III: Causes and Consequences
Seruga, B., Ocana, A., Amir, E., & Tannock, I. F. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0124 · Cited by 88
“001 PFS/TTP 19 (32) 37 (71) OS/PFS co-primary 2 (3) 3 (6) Prior phase II trials No appropriate phase II trial 21 (35) 15 (29) 0.”
BackgroundResultInfluentialPathania, S., & Singh, P. K. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1865309 · Cited by 98
“reported by Kola and Landis, established that in the 1990s pharmacokinetic failures accounted for ~40% of all attrition, however by 2000, lack of efficacy accounted for approximately 30% of failures [3].”
BackgroundGarside, H., Marcoe, K. F., Chesnut-Speelman, J., Foster, A. J., Muthas, D., Gerry Kenna, J., Warrior, U., Bowes, J., & Baumgartner, J. (2014) · Toxicology in Vitro · doi:10.1016/j.tiv.2013.10.015 · Cited by 93
Network-based characterization of drug-regulated genes, drug targets, and toxicity
Kotlyar, M., Fortney, K., & Jurisica, I. (2012) · Methods · doi:10.1016/j.ymeth.2012.06.003 · Cited by 92
The role of hepatic transporters in drug elimination
Funk, C. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.4.363 · Cited by 101
“Nowadays, it is common practice to include key DMPK assays aiming at optimized metabolic stability and pharmacokinetic properties as an integral part of new chemical programs in order to reduce the compound attrition rate [8] .”
BackgroundMehta, A. K., Chung, Y. Y., Ng, A., Iskandar, F., Atan, S., Wei, H., Dusting, G. J., Sun, W. Y., Wong, P., & SHIM, W. S. N. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvr132 · Cited by 95
“testing, preventing pharmaceutical attrition.(5,35,36) Lack of clinically relevant cell lines and costly animal models further accentuate this problem.”
BackgroundHaaker, J., Maren, S., Andreatta, M., Merz, C. J., Richter, J., Richter, S. H., Drexler, S. M., Lange, M. D., Jüngling, K., Nees, F., et al. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.09.020 · Cited by 101
Traditional Chinese Medicine and Clinical Pharmacology
Marshall, A. C. (2020) · Springer eBooks · doi:10.1007/978-3-319-68864-0_60 · Cited by 139
Synthesis and Evaluation of 3-Aroylindoles as Anticancer Agents: Metabolite Approach
Wu, Y., Coumar, M. S., Chang, J., Sun, H.-Y., Kuo, F., Kuo, C., Chen, Y.-J., Chang, C.-Y., Hsiao, C.-L., Liou, J., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900060s · Cited by 92
Reducing attrition in drug development: smart loading preclinical safety assessment
Roberts, R. A., Kavanagh, S. L., Mellor, H. R., Pollard, C. E., Robinson, S., & Platz, S. J. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.014 · Cited by 87
“Although a lack of clinical efficacy is the major cause of drug attrition, an unacceptable safety profile is also a major cause of development candidate failure [1, 7, 8], not only in the clinic, but at stages from drug candidate nomination through clinical development to postmarketing surveillance.”
BackgroundShould preclinical studies be registered?
Kimmelman, J., & Anderson, J. A. (2012) · Nature Biotechnology · doi:10.1038/nbt.2261 · Cited by 92
Urbán, P., Liptrott, N. J., & Bremer, S. (2018) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1546 · Cited by 95
Metadata
- Authors
- Kola, I., & Landis, J.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Kola, Ismail
- ORCID
- Landis, John
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-08
- Volume
- 3
- Issue
- 8
- Pages
- 711-716
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1895993106
- Cited by
- 4,167
- References
- 7
- Citations by year
- 2026: 121 · 2025: 129 · 2024: 126 · 2023: 159 · 2022: 165 · 2021: 188 · 2020: 179 · 2019: 203 · 2018: 183 · 2017: 194 · 2016: 256 · 2015: 294 · 2014: 279 · 2013: 307 · 2012: 300
- FWCI
- 199.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health and Medical Research Impacts
- Keywords
- pharmaceutical industry, attrition rates, R&D productivity, drug development costs, health care cost containment, drug costs, R&D investment
- MeSH terms
- Clinical Trials as Topic, Drug Industry, Humans, Pharmacokinetics, Drug Design, Drug Approval
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.